Characteristics of human immunodeficiency virus-1 influencing the development and efficacy of anti-HIV-1 vaccines

Dragana Božić; Nevena Arsenović Ranin; Ivan Jančić; Jelena Antić Stanković; Marina T. Milenković; Saša Vasilev; Biljana Bufan

doi:10.2298/VSP240812076B

Dragana Božić *University of Belgrade, †Faculty of Pharmacy, Department of Microbiology and Immunology, Belgrade, Serbia
Nevena Arsenović Ranin *University of Belgrade, †Faculty of Pharmacy, Department of Microbiology and Immunology, Belgrade, Serbia
Ivan Jančić *University of Belgrade, †Faculty of Pharmacy, Department of Microbiology and Immunology, Belgrade, Serbia
Jelena Antić Stanković *University of Belgrade, †Faculty of Pharmacy, Department of Microbiology and Immunology, Belgrade, Serbia
Marina T. Milenković *University of Belgrade, †Faculty of Pharmacy, Department of Microbiology and Immunology, Belgrade, Serbia
Saša Vasilev Institute for the Application of Nuclear Energy (INEP), Department of Immunology and Immunoparasitology, Belgrade, Serbia
Biljana Bufan *University of Belgrade, †Faculty of Pharmacy, Department of Microbiology and Immunology, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP240812076B

Keywords: disease transmission, infectious;, geography, medical;, hiv;, vaccines;, treatment outcome.

References

Joint United Nations Programme on HIV/AIDS (UNAIDS). Global HIV & AIDS Statistics - 2023 Fact Sheet [Internet]. Switzerland: UNAIDS 2023; [cited 2024 July 4; accessed on 2024 Sept 2]. Available from: https://www.unaids.org/en/

resources/fact-sheet

Masenga SK, Mweene BC, Luwaya E, Muchaili L, Chona M, Kirabo A. HIV-Host Cell Interactions. Cells 2023; 12(10): 1351.

Clavel F, Guétard D, Brun-Vézinet F, Chamaret S, Rey MA, Santos-Ferreira MO, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986; 233(4761): 343–6.

Ariyoshi K, Schim van der Loeff M, Berry N, Jaffar S, Whittle H. Plasma HIV viral load in relation to season and to Plasmodium falciparum parasitaemia. AIDS 1999; 13(9): 1145–6.

Ariyoshi K, Jaffar S, Alabi AS, Berry N, Schim van der Loeff M, Sabally S, et al. Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2-infected patients in West Africa. AIDS 2000; 14(4): 339–44.

Wilkins A, Ricard D, Todd J, Whittle H, Dias F, Paulo Da Silva A. The epidemiology of HIV infection in a rural area of Guinea-Bissau. AIDS 1993; 7(8): 1119–22.

Burke DS. Recombination in HIV: an important viral evolutionary strategy. Emerg Infect Dis 1997; 3(3): 253–9.

Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009; 15(8): 871–2.

Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, et al. HIV-1 nomenclature proposal. Science 2000; 288(5463): 55–7.

Vallari A, Holzmayer V, Harris B, Yamaguchi J, Ngansop C, Makamche F, et al. Confirmation of putative HIV-1 group P in Cameroon. J Virol 2011; 85(3): 1403–7.

Giovanetti M, Ciccozzi M, Parolin C, Borsetti A. Molecular Epidemiology of HIV-1 in African Countries: A Comprehensive Overview. Pathogens 2020; 9(12): 1072.

Williams A, Menon S, Crowe M, Agarwal N, Biccler J, Bbosa N, et al. Geographic and population distributions of Human Immunodeficiency Virus (HIV)-1 and HIV-2 circulating subtypes: a systematic literature review and meta-analysis (2010-2021). J Infect Dis 2023: 228(11): 1583−91.

Perrin L, Kaiser L, Yerly S. Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis 2003; 3(1): 22–7.

Lessells RJ, Katzenstein DK, De Oliveira T. Are subtype differences important in HIV drug resistance? Curr Opin Virol 2012; 2(5): 636–43.

Wainberg MA, Brenner BG. The impact of HIV genetic polymorphisms and subtype differences on the occurrence of resistance to antiretroviral drugs. Mol Biol Int 2012; 2012: 256982.

Goudsmit J. Viral Sex; The Nature of AIDS. New York (NY): Oxford University Press. 1997. p. 260.

Giovanetti M, Ciccozzi M, Parolin C, Borsetti A. Molecular Epidemiology of HIV-1 in African Countries: A Comprehensive Overview. Pathogens 2020; 9(12): 1072.

He L, Dong R, He RL, Yau SS. A novel alignment-free method for HIV-1 subtype classification. Infect Genet Evol 2020; 77: 104080.

Alexander TS. Human Immunodeficiency Virus Diagnostic Testing: 30 Years of Evolution. Clin Vaccine Immunol 2016; 23(4): 249–53.

Apetrei C, Hahn B, Rambaut A, Wolinsky S, Brister JR, Keele B, et al. HIV Sequence Compendium 2021. Published by Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, NM, LA-UR-23-22840 [Internet]. 2021 [cited 2024 June 20; accessed on 2024 Sept 3]. Available from: https://www.hiv.lanl.gov and https://www.hiv.lanl.gov/con

tent/immunology/

Stanojevic M, Alexiev I, Beshkov D, Gökengin D, Mezei M, Minarovits J, et al. HIV 1 molecular epidemiology in the Balkans: a melting pot for high genetic diversity. AIDS Rev 2012; 14(1): 28−36.

Siljic M, Salemovic D, Jevtovic D, Pesic-Pavlovic I, Zerjav S, Nikolic V, et al. Molecular typing of the local HIV-1 epidemic in Serbia. Infect Genet Evol 2013; 19: 378−85.

Ariën KK, Abraha A, Quiñones-Mateu ME, Kestens L, Vanham G, Arts EJ. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 2005; 79(14): 8979–90.

Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, et al. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 2009; 5(4): e1000365.

Zhuang J, Jetzt AE, Sun G, Yu H, Klarmann G, Ron Y, et al. Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J Virol 2002; 76(22): 11273–82.

Ramirez BC, Simon-Loriere E, Galetto R, Negroni M. Implications of recombination for HIV diversity. Virus Res 2008; 134(1-2): 64–73.

Nowak M. HIV mutation rate. Nature 1990; 347(6293): 522.

Hu WS, Temin HM. Retroviral recombination and reverse transcription. Science 1990; 250(4985): 1227–33.

Mamrosh JL, Sharon E, Fung D, Korber TMB, Brander C, Barouch D, et al. HIV Molecular Immunology 2022 [Internet]. New Mexico: Los Alamos National Laboratory, Theoretical Biology and Biophysics; 2023 [accessed on 2024 Sept 6]. Available from: https://www.hiv.lanl.gov/content/immunology/howto-cite.ht

ml

Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267(5197): 483–9.

Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373(6510): 117–22.

Song H, Giorgi EE, Ganusov VV, Cai F, Athreya G, Yoon H, et al. Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nat Commun 2018; 9(1): 1928.

Nishimura Y, Shingai M, Lee WR, Sadjadpour R, Donau OK, Willey R, et al. Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS. J Virol 2011; 85(20): 10617–26.

Nora T, Charpentier C, Tenaillon O, Hoede C, Clavel F, Hance AJ. Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment. J Virol 2007; 81(14): 7620–8.

Moutouh L, Corbeil J, Richman DD. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci USA 1996; 93(12): 6106–11.

Ritchie AJ, Cai F, Smith NM, Chen S, Song H, Brackenridge S, et al. Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. Retrovirology 2014; 11: 69.

Streeck H, Li B, Poon AF, Schneidewind A, Gladden AD, Power KA, et al. Immune-driven recombination and loss of control after HIV superinfection. J Exp Med 2008; 205(8): 1789−96.

Liu SL, Mittler JE, Nickle DC, Mulvania TM, Shriner D, Rodrigo AG, et al. Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS. J Virol 2002; 76(21): 10674−84.

Smyth RP, Davenport MP, Mak J. The origin of genetic diversity in HIV-1. Virus Res 2012; 169(2): 415−29.

McNicholl JM. Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions. Hum Vaccin Immunother 2016; 12(12): 3202–11.

Nielsen M, Marcatili P. Prediction of Antibody Epitopes. Methods Mol Biol 2015; 1348: 23–32.

Wu X, Kong XP. Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies. Curr Opin Immunol 2016; 42: 56–64.

McCoy LE, Burton DR. Identification and specificity of broadly neutralizing antibodies against HIV. Immunol Rev 2017; 275(1): 11–20.

Korber B, Hraber P, Wagh K, Hahn BH. Polyvalent vaccine approaches to combat HIV-1 diversity. Immunol Rev 2017; 275(1): 230–44.

Cerutti N, Loredo-Varela JL, Caillat C, Weissenhorn W. Antigp41 membrane proximal external region antibodies and the art of using the membrane for neutralization. Curr Opin HIV AIDS 2017; 12(3): 250–6.

Yoon H, Macke J, West AP Jr, Foley B, Bjorkman PJ, Korber B, et al. CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. Nucleic Acid Res 2015; 43(W1): W213–9.

Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol 2015; 16(6): 571–6.

Landais E, Moore PL. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. Retrovirology 2018; 15(1): 61.

Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 2014; 28(2): 163–9.

Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 2011; 85(10): 4828–40.

Burton DR, Hangartner L. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. Annu Rev Immunol 2016; 34: 635–59.

Kelsoe G, Haynes BF. Host controls of HIV broadly neutralizing antibody development. Immunol Rev 2017; 275(1): 79–88.

Wibmer CK, Moore PL, Morris L. HIV broadly neutralizing antibody targets. Curr Opin HIV AIDS 2015; 10(3): 135–43.

Boesch AW, Brown EP, Ackerman ME. The role of Fc receptors in HIV prevention and therapy. Immunol Rev 2015; 268(1): 296–310.

Pollara J, Bonsignori M, Moody MA, Pazgier M, Haynes BF, Ferrari G. Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Curr HIV Res 2013; 11(5): 378–87.

Girard MP, Picot V, Longuet C, Nabel GJ. Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV. Part 2: Non-neutralizing antibodies: Fondation Mérieux Conference Center, Veyrier du Lac, France 5–7 November 2012. Vaccine 2013; 31(29): 2984–7.

Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009; 4(5): 388–93.

Sahay B, Nguyen CQ, Yamamoto JK. Conserved HIV Epitopes for an Effective HIV Vaccine. J Clin Cell Immunol 2017; 8(4): 518.

Létourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, Yang H, et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2007; 2(10): e984.

Ondondo B, Murakoshi H, Clutton G, Abdul-Jawad S, Wee EG, Gatanaga H, et al. Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. Mol Ther 2016; 24(4): 832–42.

Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007; 13(1): 100–6.

Sanou MP, Roff SR, Mennella A, Sleasman JW, Rathore MH, Yamamoto JK, et al. Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects. J Virol 2013; 87(18): 10004–15.

Roff SR, Sanou MP, Rathore MH, Levy JA, Yamamoto JK. Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects. Hum Vaccin Immunother 2015; 11(6): 1540–56.

Ferguson AL, Mann JK, Omarjee S, Ndung'u T, Walker BD, Chakraborty AK. Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. Immunity 2013; 38(3): 606–17.

Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10(3): 282–9.

Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ebrahimsa U, et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 2014; 22(2): 464–75.

Hanke T. Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. Expert Opin Biol Ther 2014; 14(5): 601–16.

Samri A, Bacchus-Souffan C, Hocqueloux L, Avettand-Fenoel V, Descours B, Theodorou I, et al. Polyfunctional HIV-specific T cells in Post-Treatment Controllers. AIDS 2016; 30(15): 2299–302.

De Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012; 188(10): 5166–76.

Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T, et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med 2012; 4(123): 123ra25.

MacDonald KS, Fowke KR, Kimani J, Dunand VA, Nagelkerke NJ, Ball TB, et al. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2000; 181(5): 1581–9.

MacDonald KS, Embree JE, Nagelkerke NJ, Castillo J, Ramhadin S, Njenga S, et al. The HLA A2/6802 supertype is associated with reduced risk of perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 183(3): 503–6.

Koehler RN, Walsh AM, Saathoff E, Tovanabutra S, Arroyo MA, Currier JR, et al. Class I HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania. J Infect Dis 2010; 202(10): 1562–6. Erratum in: J Infect Dis 2011; 203(5): 749.

Peterson TA, Kimani J, Wachihi C, Bielawny T, Mendoza L, Thavaneswaran S, et al. HLA class I associations with rates of HIV-1 seroconversion and disease progression in the Pumwani Sex Worker Cohort. Tissue Antigens 2013; 81(2): 93–107.

Liu C, Carrington M, Kaslow RA, Gao X, Rinaldo CR, Jacobson LP, et al. Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2003; 187(9): 1404–10.

Farquhar C, Rowland-Jones S, Mbori-Ngacha D, Redman M, Lohman B, Slyker J, et al. Human leukocyte antigen (HLA) B*18 and protection against mother-to-child HIV type 1 transmission. AIDS Res Hum Retroviruses 2004; 20(7): 692–7.